Amicus Therapeutics, Inc., founded in 2002, is a company that specializes in biotechnology and is among the leaders of advanced therapies treating an array of diseases.
Amicus Therapeutics works with a personalized medicine, known as Migalastat. This medicine treats patients with Fabry disease. In addition, the company also works with SD-101. This medicine is a promising treatment option for a rare connective tissue disease called Epidermolysis. Amicus Therapeutics uses Chaperone-Advanced Replacement Therapy to make enzyme replacement therapies to treat issues like Fabry disease, Pompe disease, and Lysosomal Storage Disorders.
Amicus Therapeutics uses advanced technology to create treatment options that treat mutated proteins that lead to genetic disorders (http://weeklyopinion.com/2017/08/amicus-therapeutics-announces-the-launch-of-new-drug/). The company and the scientists who work for the organization are fueled by their passion and dedication to finding treatments and potential cures for rare diseases.
Amicus Therapeutics is not only dedicated to research and findings but also dedicated to the patients who these treatments will benefit. The company works with patient organizations, patients, caregivers, and other professionals to provide support for people suffering from rare diseases. Amicus serves as a bridge between patients and all the resources and support they need while dealing with diseases and receiving treatment. It is their goal to assist in the healing of their disease and also healing that goes beyond rare disorders. Through education, support, and advocacy, the company works to be a top resource for patients from all areas of healing and management of diseases.
Amicus Therapeutics provides the most trusts and respect for colleagues (Indeed). Through support and understanding that everyone in all department shares responsibility, the company is able to remain unique and special in the commitment it has to the research of biotechnology and the patients it serves.